| CELCUITY INC. DL -,001 |
| USA |
| Gesundheit |
| US15102K1007 / A2JAAX |
| 7VR (Frankfurt) / CELC (NASDAQ) |
| FRA:7VR, ETR:7VR, 7VR:GR, NASDAQ:CELC |
| - |
| https://www.celcuity.com/ |
|
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets ..
>Volltext.. |
| 4716.36 Mio. EUR |
| 4612.75 Mio. EUR |
| - |
| -149.03 Mio. EUR |
| -153.37 Mio. EUR |
| -3.28 EUR |
| 278.87 Mio. EUR |
| 143.55 Mio. EUR |
| -132.79 Mio. EUR |
| 10 |
| - |
| -58.39% |
| - |
| - |
| - |
| CELCUITY |
| 05.04.26 |
|